Alberta Collaborative QI Strategies to Improve Outcomes of Moderate and Late Preterm Infants (ABC-QI Trial)
Launched by UNIVERSITY OF CALGARY · Jan 28, 2022
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
The ABC-QI Trial is a study focused on improving the care of preterm infants born between 32 and 36 weeks of pregnancy who need extra help in the hospital. The goal of the trial is to find out if using specific strategies and evidence-based care practices can help these babies leave the hospital sooner and go home to their families. The study is taking place in neonatal intensive care units (NICUs) across Alberta and is currently recruiting participants.
To be eligible for the study, babies must be born preterm (between 32 to 36 weeks) and admitted to one of the participating NICUs. Unfortunately, infants with serious birth defects or those who need immediate surgery at certain hospitals are not eligible. Families can expect that their baby's care will be part of this quality improvement effort, which aims to provide the best possible outcomes by making hospital stays shorter and more effective.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Preterm Infants: Infants born at 32 to 36 weeks' gestation and admitted to the participating NICUs or postpartum units.
- • Quality Improvement Implementation Survey version 2 (QIIS-II) and semi-structured interview participants: Management staff, nurses, nurse practitioners, physicians, and allied health staff employed in participating NICUs.
- Exclusion Criteria:
- * Preterm Infants:
- • Major congenital anomalies or chromosomal abnormalities.
- • Primary admission to a surgical NICU: Alberta Children's Hospital or Stollery Children's Hospital.
- • Infants born in or transferred to a NICU outside Alberta.
- • Patients who have imposed confidentiality restrictions on accessing their health records.
About University Of Calgary
The University of Calgary is a leading research institution dedicated to advancing health and science through innovative clinical trials. With a strong emphasis on multidisciplinary collaboration, the university's clinical research initiatives aim to address pressing health challenges and improve patient outcomes. The institution fosters a robust environment for academic inquiry, leveraging state-of-the-art facilities and a diverse network of experts in various fields. Committed to ethical research practices and community engagement, the University of Calgary strives to translate scientific discoveries into tangible benefits for society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Calgary, Alberta, Canada
Edmonton, Alberta, Canada
Edmonton, Alberta, Canada
Calgary, Alberta, Canada
Lethbridge, Alberta, Canada
Calgary, Alberta, Canada
Calgary, Alberta, Canada
Edmonton, Alberta, Canada
Edmonton, Alberta, Canada
Calgary, Alberta, Canada
Red Deer, Alberta, Canada
Medicine Hat, Alberta, Canada
Calgary, Alberta, Canada
Patients applied
Trial Officials
Ayman Abou Mehrem, MD
Principal Investigator
University of Calgary
Jennifer Toye, MD
Principal Investigator
University of Alberta
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials